Donor‐derived malignancy: transmission of small‐cell lung cancer via renal transplantation.

Winter, Thomas C.; Keller, Patrick R.; Lee, Fred T.; Pozniak, Myron A.

doi:10.7863/jum.2001.20.5.559

Cited by 16 publications

(17 citation statements)

References 11 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…58 Transmission of small-cell lung cancer via renal as well as glioblastoma via liver transplantation has been reported. 40,41 It should be mentioned that malignancies arising in recipients after HCT or solid organ transplantation are not always caused by transmission of the disease from donor to recipient, but might develop in donor cells as secondary malignancies. 59 The most common donor cell malignancy is PTLD, but other secondary malignancies have also been observed after HCT and solid organ transplantation.…”

Section: Transmission Of Donor Illness By Stem Cell Transplantation Dmentioning

confidence: 99%

Transmission of donor illness by stem cell transplantation: should screening be different in older donors?

Niederwieser¹,

Gentilini²,

Hegenbart³

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:With increasing donor age, the potential of transmitting diseases from donor to recipient reaches new dimensions. Potentially transmittable diseases from donors include infections, congenital disorders, and acquired illnesses like autoimmune diseases or malignancies of hematological or nonhematological origin. While established nonmalignant or malignant diseases might be easy to discover, earlystage hematological diseases like CML, light-chain multiple myelomas, aleukemic leukemias, occult myelodysplastic syndromes and other malignant and nonmalignant diseases might not be detectable by routine screening but only by invasive, new and/or expensive diagnostic tests. In the following article, we propose recommendations for donor work-up, taking into consideration the age of the donors. In contrast to blood transfusions, stem cells from donors with abnormal findings might still be acceptable for HCT, when no other options are available and life expectancy is limited. This issue is discussed in detail in relation to the available donor and stem cell source. Finally, the recommendations presented here aim at harmonized worldwide work-up for donors to insure high standard quality.

show abstract

Section: Transmission Of Donor Illness By Stem Cell Transplantation Dmentioning

confidence: 99%

Transmission of donor illness by stem cell transplantation: should screening be different in older donors?

Niederwieser¹,

Gentilini²,

Hegenbart³

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Besides these retrospective studies there have been many case reports of tumor transmission (melanoma, sarcoma, renal cell carcinoma, etc) (Stephens et al 2000;Milton et al 2006;Neipp et al 2006;Cankovic et al 2006;Detry et al 2005;Morris-Stiff et al 2004;Gerstenkorn and Thomusch 2003;Lipshutz et al 2003;Loren et al 2003;Kakar et al 2002;Barrou et al 2001;Winter et al 2001;Conlon and Smith 1995;Oesterwitz and Lucius 1991;Barnes and Fox 1976), some of which may have been included in the reviews described.…”

Section: Non-cns Tumor-transmissionmentioning

confidence: 95%

Donor derived malignancy following transplantation: a review

Gandhi

Strong

2007

Cell Tissue Banking

View full text Add to dashboard Cite

Organ and tissue transplant is now the treatment of choice for many end stage diseases. In the recent years, there has been an increasing demand for organs but not a similar increase in the supply leading to a severe shortage of organs for transplant resulted in increasing wait times for recipients. This has resulted in expanded donor criteria to include older donors and donors with mild disease. In spite of implementation of more stringent criteria for donor selection, there continues to be some risk of donor derived malignancy. Malignancy after transplantation can occur in three different ways: (a) de-novo occurrence, (b) recurrence of malignancy, and (c) donor-related malignancy. Donor related malignancy can be either due to direct transmission of tumor or due to tumor arising in cells of donor origin. We will review donor related malignancies following solid organ transplantation and hematopoeitic progenitor cell transplantation. Further, we will briefly review the methods for detection and management of these donor related malignancies.

show abstract

“…There have been few reported cases in which transplanted organs contained occult tumors that subsequently developed metastases (1)(2)(3)(4)(5). There have been few reported cases in which transplanted organs contained occult tumors that subsequently developed metastases (1)(2)(3)(4)(5).…”

Section: Donor-derived Small Cell Lung Carcinoma In a Transplanted Kimentioning

confidence: 99%

Donor-Derived Small Cell Lung Carcinoma in a Transplanted Kidney

Göbel¹,

Gloy²,

Neumann³

et al. 2007

Transplantation

View full text Add to dashboard Cite

Donor‐derived malignancy: transmission of small‐cell lung cancer via renal transplantation.

Abstract: onor-derived malignancy (the inadvertent transmission of a tumor from the donor to the transplant recipient) is a rare phenomenon. We present an imaging report showing transmission of small-cell lung cancer from the donor to the recipient via a transplanted kidney.

Cited by 16 publications

References 11 publications

Transmission of donor illness by stem cell transplantation: should screening be different in older donors?

Transmission of donor illness by stem cell transplantation: should screening be different in older donors?

Donor derived malignancy following transplantation: a review

Donor-Derived Small Cell Lung Carcinoma in a Transplanted Kidney

Contact Info

Product

Resources

About